- Forums
- ASX - By Stock
- Neuren Media and Analyst Coverage
no benefits from the angelman trial?
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.85 |
Change
-0.380(2.34%) |
Mkt cap ! $2.034B |
Open | High | Low | Value | Volume |
$16.33 | $16.37 | $15.78 | $7.063M | 441.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 26 | $15.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.85 | 297 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 493 | 15.860 |
16 | 1213 | 15.850 |
6 | 502 | 15.840 |
4 | 354 | 15.830 |
6 | 479 | 15.820 |
Price($) | Vol. | No. |
---|---|---|
15.870 | 650 | 7 |
15.880 | 400 | 5 |
15.890 | 318 | 4 |
15.900 | 501 | 7 |
15.910 | 274 | 2 |
Last trade - 14.54pm 13/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online